January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
November 2024 in “EMBO Molecular Medicine” JAK inhibitors may reverse early hair loss, but prolonged inflammation can cause permanent hair loss.
July 2024 in “Brazilian Journal of Clinical Medicine and Review” Hair loss after bariatric surgery is common due to nutrient deficiencies and rapid weight loss.
February 2024 in “Medicina-lithuania” Obesity and bariatric surgery can cause hair thinning and temporary hair loss due to nutritional deficiencies and stress.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
April 2026 in “Al-Kufa University Journal for Biology” Zinc and iron levels drop after bariatric surgery, needing careful monitoring and supplements.
March 2026 in “Indian Journal of Dermatology” Baricitinib can cause excessive hair growth.
February 2026 in “Austrian Journal of Technical and Natural Sciences” Mesotherapy may help treat hair loss in patients after bariatric surgery.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
January 2026 in “JAAD International” Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
January 2026 in “International Journal of Nutrology” Hair loss is common after bariatric surgery, especially vertical sleeve gastrectomy, and is linked to emotional distress.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
December 2025 in “Saudi Journal of Medicine and Public Health” Bariatric surgery can cause long-term issues like hair loss, mood swings, and weight regain, needing ongoing care and education.
December 2025 in “Medicina” Bariatric surgery improved quality of life and health in six months, but hair loss was common.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
December 2025 in “The American Journal of Medical Sciences and Pharmaceutical Research” Combining barber scalp care with medical treatment improves scalp health and well-being in early-stage alopecia.
Barbers trained in hair loss can better support and refer clients with alopecia.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.